Evaluation of Celsior® in Liver Transplant Preservation.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00151593
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : November 26, 2007
Sangstat Medical Corporation
Information provided by:
Rennes University Hospital

Brief Summary:
The aim of the study is to determine the efficacy and safety of a preservation solution in liver transplantation. Its efficacy will be compared to the efficacy of other currently used preservation solutions.

Condition or disease Intervention/treatment Phase
Liver Transplantation Other: Celsior® Phase 2

Detailed Description:

The quality of organ preservation is a major determinant of initial graft function and survival. Graft viability is based on hypothermia, the organ being stored in a cold preservation solution.

Celsior® has been shown effective for cold preservation of heart and lung and, in laboratory studies, for liver, kidney and pancreas. The aim of the study is to evaluate the efficacy and safety of Celsior® in liver transplant preservation. Celsior® will be considered effective if the failure rate one year after transplantation is not significantly superior to 20% (rate observed in the European transplantation register between 1997 and 2001).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 140 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Celsior®: Evaluation of an Organ Preservation Solution in Liver Transplantation.
Study Start Date : February 2002
Actual Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Celsior preservation solution
Other: Celsior®
Graft preservation solution

Primary Outcome Measures :
  1. Graft failure leading to patient death or retransplantation [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Onset and severity of hemodynamic troubles at reperfusion [ Time Frame: Reperfusion after transplantation ]
  2. Onset of surgical complications [ Time Frame: 1 year ]
  3. Liver graft function during the fourteen first days [ Time Frame: 14 days ]
  4. Incidence, treatment and evolution of acute and chronic rejections histologically proven [ Time Frame: 1 year ]
  5. Onset of infections [ Time Frame: 1 year ]
  6. Onset, treatment and evolution of serious adverse events [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult
  • Primary liver transplantation
  • Whole organ transplantation
  • Agreement for a 1 year follow-up
  • Informed written consent

Exclusion Criteria:

  • Liver disease secondary to clotting abnormalities
  • Uncontrolled bacterial or viral disease at the time of transplantation
  • Combined transplantations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00151593

Service de Chirurgie Digestive - Hôpital de la Côte de Nacre
Caen, France, 14033
Service de Chirurgie Digestive - Hôpital Henri Mondor
Créteil, France, 94010
Service de Chirurgie Viscérale et Transplantations - Hôpital Dupuytren
Limoges, France, 87042
Chirurgie générale et digestive - Hôpital de la Croix Rousse
Lyon, France, 69317
Service de Chirurgie Générale - Hôpital Edouard Herriot
Lyon, France, 69437
Service de Chirurgie Générale - Hôpital de la Conception
Marseille, France, 13385
Service de Chirurgie Générale et Digestive - Hôpital Cochin
Paris, France, 75679
Département de Chirurgie Viscérale - Hôpital Pontchaillou
Rennes, France, 35033
Service de Chirurgie Générale et Transplantation Multi-organe - Hôpital de la Hautepierre
Strasbourg, France, 67098
Sponsors and Collaborators
Rennes University Hospital
Sangstat Medical Corporation
Study Director: Karim Boudjema, MD, PhD CHU Rennes
Study Chair: Eric Bellissant, MD, PhD CHU Rennes